Savara hunts cash af­ter dou­bling down on late-stage res­pi­ra­to­ry drugs

Austin-based Savara Ther­a­peu­tics got start­ed in biotech with a list of an­gel in­vestors and a lead pro­gram that looked to de­vel­op an in­haled dry pow­der for­mu­la­tion of van­comycin for cys­tic fi­bro­sis suf­fer­ers. Now, with its Phase III loom­ing at the end of the year, the com­pa­ny has lined up an­oth­er late-stage ther­a­py, pick­ing up the res­pi­ra­to­ry as­sets of Dan­ish biotech Seren­dex in an ac­qui­si­tion as it hunts up fresh mil­lions to do a con­sid­er­able amount of de­vel­op­ment work.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER